No Data
Kintor Pharmaceutical Enrolls First Patient in Alopecia Drug Phase 3 Trial in China
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
KINTOR PHARMA-B (09939.HK): The key Phase III clinical trial for KX-826 solution 1.0% treating androgenetic alopecia in adult men in China has completed the enrollment of the first subject.
On December 30, Gelonghui reported that KINTOR PHARMA-B (09939.HK) announced the successful completion of the first subject enrollment in the critical clinical trial of KX-826 solution 1.0% for treating androgenetic alopecia in adult men in China, which recently entered Phase III ("this Phase III"). This critical clinical trial is a multicenter, randomized, double-blind, placebo-controlled adaptive design study aimed at evaluating the efficacy and safety of topical KX-826 solution 1.0% for treating Chinese adult men with AGA.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
